Drugs / CRD-4730
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06658899 | Dec 2025 → Apr 2027 expected | catecholaminergic polymorphic ventricular tachycardia | Cardurion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06005428 | Nov 2023 → May 2025 | catecholaminergic polymorphic ventricular tachycardia 1, congenital heart defects, multiple types | Cardurion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRD-4730 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06658899 ↗ |
| Route | Oral | “when administered as single oral doses” NCT06005428 ↗ |